March 16, 2017
Stada confirms postponing Board bidding session
Stada’s Supervisory Board has postponed expert sessions which were planned as part of the structured bidding process.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
March 16, 2017
Bone Therapeutics reports €13 million net loss for 2016
Bone Therapeutics, the bone cell therapy company, has reported net loss of €13,02 million for 2016 which is slight decrease in loss comaring to last years €14,07 million net loss.
March 16, 2017
Shire gets European approval for Llabel extension of Cinryze
Shire said on Thursday that the European Commission (EC) has approved a label extension granting three new indications for CINRYZE® (C1 inhibitor [human]), broadening its use to children with Hereditary angiodema (HAE), a rare, genetic disorder that results in recurring attacks of edema (swelling). The body sites most commonly affected are mainly the extremities and abdomen.
March 16, 2017
Cresco’s subsidiary gets approval in Czech Republic for one of its products
Creso Pharma’s subsidiary HempIndustries s.r.o. (HI) has received regulatory approval in the Czech Republic to sell its new product line called diCBDIUM.
The approval by the Czech Ministry of Agriculture, means that HI can …
March 15, 2017
Severe asthma market is driving Nucala sales, opportunity for Teva, AstraZeneca, Sanofi, and Regeneron
Decision Resources Group (DRG) finds that Nucala’s novel mechanism of action and specific indication for eosinophilic asthma are key drivers behind the agent’s recent success in the severe asthma market.
March 15, 2017
BASF raises ethonalomines prices in Europe
BASF, German based chemical company, has reported that it has raised prices of ethanolamines in Europe, effective immediately.
March 15, 2017
OptiBiotix confimrs new board members
OptiBiotix has confirmed today that Per Rehné and Christina Wood have been appointed to the Board of OptiBiotix. The company in January announced naming the new members.
March 14, 2017
Tiziana Life Sciences welcomes liver specialist to its Scientific Advisory Board
Tiziana Life Sciences, a clinical stage biotechnology company developing targeted drugs for cancer, autoimmune and inflammatory diseases, has appointed Dr. Arun Sanyal as a new member of its Scientific Advisory Board.
March 14, 2017
FDA OK’s Novartis’s breast cancer drug
The US Food and Drug Administration (FDA) has approved Novartis’s Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
March 13, 2017
Ipsen wins MHRA’s approval for its breast cancer drug
Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, in coordination with fourteen other European regulatory agencies, has approved a new indication for Ipsen’s Decapeptyl as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy.